Landiolol, an intravenous β1-selective blocker, is useful for dissociating a fusion of atrial activation via accessory pathway and atrioventricular node.
Takahiko KinjoMasaomi KimuraNoriyoshi KanameDaisuke HoriuchiTaihei ItohYuji IshidaKimitaka NishizakiYuichi ToyamaShingo SasakiHirofumi TomitaPublished in: Journal of arrhythmia (2023)
Landiolol inhibited the AV node without affecting the AP and helped dissociate a fusion of atrial activation at a lower ventricular pacing rate.